Cover Image
市場調查報告書

細胞重定向雙特異性抗體:相關利益者、技術、開發平台、交易的競爭情形分析

T-Cell Redirecting Bispecific Antibodies 2016: A Competitive Landscape Analysis of Stakeholders, Technologies, Pipelines and Deals

出版商 La Merie Publishing 商品編碼 357780
出版日期 內容資訊 英文 230 Pages
訂單完成後即時交付
價格
Back to Top
細胞重定向雙特異性抗體:相關利益者、技術、開發平台、交易的競爭情形分析 T-Cell Redirecting Bispecific Antibodies 2016: A Competitive Landscape Analysis of Stakeholders, Technologies, Pipelines and Deals
出版日期: 2016年05月11日 內容資訊: 英文 230 Pages
簡介

本報告提供T細胞/NK細胞重定向雙特異性抗體分子調查分析,推薦的標的,分子結構,服藥計劃,臨床經驗,聯合治療,其他的治療方法的競爭等系統性資訊。

第1章 簡介

第2章 摘要整理

第3章 競爭情形分析

  • 相關利益者
  • 技術
  • 開發平台
  • 標的、醫藥品、技術的商業性價值

第4章 企業簡介

  • 大製藥、生物科技企業
    • Amgen
    • AstraZeneca
    • Bayer
    • Boehringer Ingelheim
    • Eli Lilly
    • GlaxoSmithKline
    • Janssen Biotech
    • Pfizer
    • Roche
    • Servier
  • 中小製藥、生物科技企業
    • Adimab
    • Affimed Therapeutics
    • Alligator Biosciences
    • Ambrx
    • CytomX
    • Emergent BioSolutions
    • EngMab
    • Eureka Therapeutics
    • GEMoaB
    • Generon
    • Genmab
    • Glenmark Pharmaceuticals
    • Immunocore
    • MacroGenics
    • Merus
    • Molecular Partners
    • Morphosys
    • Neovii Biotech
    • OMT Therapeutics
    • Pieris
    • Regeneron Pharmaceuticals
    • Wuhan YZY Biopharma
    • Xencor
    • Zymeworks

第5章 技術簡介

  • ADAPTIR
  • ART-Ig
  • Azymetric Scaffold
  • BEAT
  • Biclonics
  • BiTE
  • CrossMab
  • DART
  • Fc-DART
  • Dock-and-Lock (DNL)
  • DuoBody
  • FynomAbs
  • ImmTAC
  • Knobs-into-Holes
  • mAbXcite
  • Modified VelocImmune
  • TandAb
  • T-Cell Engaging Bi-specific (TCB) Probody
  • Triomab
  • UniDab
  • UniTARG/UniMAB
  • XmAb Bispecific
  • Y-Body Bispecific

第6章 醫藥品、候補藥簡介

  • A-337
  • AFM11
  • AFM13
  • AFM21
  • AFM22
  • AFM24
  • AMG 221
  • AMG 330
  • AMV-564
  • BI 836909
  • Bispecific anti-CD3-folate
  • Blincyto
  • CD79b-TDB
  • COVA420
  • DR5xCD3 DART
  • EM801
  • EphA2xCD3 DART
  • ERY974
  • ES414
  • ES425
  • GBR1302
  • GBR1342
  • Her2-TDB
  • IL13Rα DART
  • IMCgp100
  • JNJ-63709178
  • JNJ-64052781
  • M-706
  • M-802
  • MCLA-117
  • MGD006
  • MGD007
  • MGD009
  • MGD014
  • Pasotuxizumab
  • PF-06671008
  • PRS-343
  • PSMA-CD3
  • REGN1979
  • Removab
  • RG7802
  • RG7828
  • ROR1xCD3 DART
  • XmAb13551
  • XmAb13676
  • XmAb14045
  • ZW38

第7章 參考資料

第8章 附錄

圖表

目錄
Product Code: LMFR0018

Immunotherapy of cancer with direct or indirect use of T-cells is one of the most exciting fields of cancer research. Direct T-cell therapy implies the ex vivo engineering of autologous or allogeneic T-cells for tumor targeting by chimeric antigen receptors (CAR) or T-cell receptors (TCR). Despite stunning clinical results with CD19-targeted CAR T-cells, many major pharmaceutical companies have not embarked on this field of adoptive cell therapy, probably because cell products are a world completely different from that of small molecules or recombinant proteins and antibodies.

Tremendous progress in bispecific antibody technologies during the last decade and the clinical success of a first generation bispecific T-cell engager (BiTE) antibody molecule directed against CD19 lead to an explosion of T-cell redirecting bispecific antibodies in clinical development. Within 18 months, the number of clinical stage T-cell or natural killer (NK) cells redirecting bispecific antibodies has increased from 4 to 21 and further 16 molecules could enter clinical development within the next 12 months.

This report“T-Cell Redirecting Bispecific Antibodies 2016: A competitive landscape analysis of stakeholders, technologies, pipelines and deals” as of May 2016 brings you up-to-date information about and analysis of 34 corporate players, 22 key technologies, 47 T-cell and NK-cell redirecting bispecific antibody profiles, business deals and private and public financing rounds.

The report analyzes the pipeline of T-cell and NK-cell redirecting bispecific antibody molecules regarding preferred targets, molecular constructs, dosing schedules, clinical experience, combination study plans, competition with other treatment modalities and the next wave of T-cell and NK-cell redirecting antibodies.

Preferences in bispecific antibody technologies are evaluated regarding drug candidate output, partnering, technological features and impact on clinical administration regimens.

All information in the report is fully referenced with 159 scientific references, in many cases with hyperlinks leading to the source of information (abstracts, Posters, papers). Non-scientific references, such as press releases, annual reports or company presentations are disclosed within the text with an embedded hyperlink leading to the online source of information.

What will you find in the report?

  • Profiles of 34 companies active in the field;
  • Comprehensive description of 23 established and emerging T-cell or NK-cell redirecting antibodies
  • Profiles of two approved and 45 T-cell or NK-cell redirecting bispecific antibodies in all phases of development;
  • Technology selection and preferences of major pharma;
  • Key characteristics of technologies with clinical stage drug candidates
  • Emerging alternative bi- and trispecific formats
  • Target selection and competition in drug candiates
  • Competition of recombinant bispecific molecules with alternative treatment modalities
  • Dosing schedules of clinical stage drug candidates based on molecular features
  • Economic terms of collaboration and licensing deals;

Table of Contents

1. Introduction

2. Executive Summary

3. Competitive Landscape Analysis

  • 3.1. Stakeholders
    • 3.1.1. Major biopharmaceutical companies
    • 3.2.2. Small & medium pharmaceutical & biotechology companies
  • 3.2. Technologies
  • 3.3. Pipeline
    • 3.3.1. Overview
    • 3.3.2. Targets
    • 3.3.3. Competition with other Treatment Modalities
    • 3.3.4. Administration Regimens of T-cell Redirecting Bispecific Antibodies
    • 3.3.5. Next Wave of T-cell and NK-Cell Redirecting Antibodies
    • 3.3.6. Clincial Experience with T-cell and NK-cell redirecting Bispecific Antibodies
  • 3.4. Commercial value of targets, drugs & technologies
    • 3.4.1. Drug prices and sales
    • 3.4.2. Economic terms of collaboration and licensing agreements
    • 3.4.3. Acquisition price (cost) of companies
    • 3.4.4. Public and private financing rounds

4. Company Profiles

  • 4.1. Major Pharma & Biotech
    • 4.1.1. Amgen
    • 4.1.2. AstraZeneca
    • 4.1.3. Bayer
    • 4.1.4. Boehringer Ingelheim
    • 4.1.5. Eli Lilly
    • 4.1.6. GlaxoSmithKline
    • 4.1.7. Janssen Biotech
    • 4.1.8. Pfizer
    • 4.1.9. Roche
    • 4.1.10. Servier
  • 4.2. Small & Medium Pharma & Biotech
    • 4.2.1. Adimab
    • 4.2.2. Affimed Therapeutics
    • 4.2.3. Alligator Biosciences
    • 4.2.4. Ambrx
    • 4.2.5. CytomX
    • 4.2.6. Emergent BioSolutions
    • 4.2.7. EngMab
    • 4.2.8. Eureka Therapeutics
    • 4.2.9. GEMoaB
    • 4.2.10. Generon
    • 4.2.11. Genmab
    • 4.2.12. Glenmark Pharmaceuticals
    • 4.2.13. Immunocore
    • 4.2.14. MacroGenics
    • 4.2.15. Merus
    • 4.2.16. Molecular Partners
    • 4.2.17. Morphosys
    • 4.2.18. Neovii Biotech
    • 4.2.19. OMT Therapeutics
    • 4.2.20. Pieris
    • 4.2.21. Regeneron Pharmaceuticals
    • 4.2.22. Wuhan YZY Biopharma
    • 4.2.23. Xencor
    • 4.2.24. Zymeworks

5. Technology Profiles

  • 5.1. ADAPTIR
  • 5.2. ART-Ig
  • 5.3. Azymetric Scaffold
  • 5.4. BEAT
  • 5.5. Biclonics
  • 5.6. BiTE
  • 5.7. CrossMab
  • 5.8. DART
  • 5.9. Fc-DART
  • 5.10. Dock-and-Lock (DNL)
  • 5.11. DuoBody
  • 5.12. FynomAbs
  • 5.13. ImmTAC
  • 5.14. Knobs-into-Holes
  • 5.15. mAbXcite
  • 5.16. Modified VelocImmune
  • 5.17. TandAb
  • 5.18. T-Cell Engaging Bi-specific (TCB) Probody
  • 5.19. Triomab
  • 5.20. UniDab
  • 5.21. UniTARG / UniMAB
  • 5.22. XmAb Bispecific
  • 5.23. Y-Body Bispecific

6. Drug & Drug Candidate Profiles

  • 6.1. A-337
  • 6.2. AFM11
  • 6.3. AFM13
  • 6.4. AFM21
  • 6.5. AFM22
  • 6.6. AFM24
  • 6.7. AMG 221
  • 6.8. AMG 330
  • 6.9. AMV-564
  • 6.10. BI 836909
  • 6.11. Bispecific anti-CD3-folate
  • 6.12. Blincyto
  • 6.13. CD79b-TDB
  • 6.14. COVA420
  • 6.15. DR5xCD3 DART
  • 6.16. EM801
  • 6.17. EphA2xCD3 DART
  • 6.18. ERY974
  • 6.19. ES414
  • 6.20. ES425
  • 6.21. GBR1302
  • 6.22. GBR1342
  • 6.23. Her2-TDB
  • 6.24. IL13Rα DART
  • 6.25. IMCgp100
  • 6.26. JNJ-63709178
  • 6.27. JNJ-64052781
  • 6.28. M-706
  • 6.29. M-802
  • 6.30. MCLA-117
  • 6.31. MGD006
  • 6.32. MGD007
  • 6.33. MGD009
  • 6.34. MGD014
  • 6.35. Pasotuxizumab
  • 6.36. PF-06671008
  • 6.37. PRS-343
  • 6.38. PSMA-CD3
  • 6.39. REGN1979
  • 6.40. Removab
  • 6.41. RG7802
  • 6.42. RG7828
  • 6.43. ROR1xCD3 DART
  • 6.44. XmAb13551
  • 6.45. XmAb13676
  • 6.46. XmAb14045
  • 6.47. ZW38

7. References

8. Attachment

List of Tables

  • Table 1: Technologies Used by Big Pharma / Biotech in Clinical Stage T-Cell Redirecting Bispecific Antibodies and Compared with Related Technologies
  • Table 2: T-Cell & NK-Cell Redirecting Bispecific Antibody Technologies from Small & Medium Pharmaceutical Companies and their Licensees
  • Table 3: Technology Features of Clinical Stage T-Cell & NK-Cell Redirecting Bispecific Antibody Technologies
  • Table 4: Corporate T-Cell and NK-Cell Redirecting Bispecific Antibody Technologies
  • Table 5: Targets for T-Cell & NK-Cell Redirecting Bispecific Antibodies
  • Table 6: Target Competition by Treatment Modalities
  • Table 7: Technology-Dependent Administration Regimens of Clinical Stage T-Cell & NK-Cell Redirecting Bispecific Antibodies
  • Table 8: Next Wave of T-Cell and NK-Cell Redirecting Bispecific Antibodies
  • Table 9: Economic Terms of Licensing Agreements for T-Cell Redirecting Bispecific Antibodies
  • Table 10: Clinical Development Indications and Status of Blincyto
  • Table 11: BiTE Development Pipeline by Amgen and/or Partners
  • Table 12: Affimed's TandAb Pipeline
  • Table 13: Goals and Terms of Immunocore's Partnering Deals for ImmTAC Technology
  • Table 14: YZY Biopharma's Pipeline of T-Cell Redirecting Bispecific Antibodies
  • Table 15: Clinical Studies with Blincyto (blinatumomab)
  • Table 16: Clinical Stage T-Cell and NK-Cell Redirecting Bispecific Antibodies
  • Table 17: Clinical Combination Studies with T-Cell and NK-Cell Redirecting Bispecific Antibodies
  • Table 18: T-Cell and NK-Cell Redirecting Bispecific Antibodies in IND and IND-Enabling Study Phase
  • Table 19: T-Cell and NK-Cell Redirecting Bispecific Antibodies in Preclinical R&D

List of Companies

  • Adimab
  • Affimed Therapeutics
  • Alligator Biosciences
  • Ambrx
  • Amgen
  • AstraZeneca
  • Bayer
  • Boehringer Ingelheim
  • CytomX
  • Eli Lilly
  • Emergent BioSolutions
  • EngMab
  • Eureka Therapeutics
  • GEMoaB
  • Generon
  • Genmab
  • GlaxoSmithKline
  • Glenmark Pharmaceuticals
  • ImmuneXcite
  • Immunocore
  • Immunomedics
  • Janssen Biotech
  • MacroGenics
  • Merus
  • Molecular Partners
  • Morphosys
  • Neovii Biotech
  • OMT Therapeutics
  • Pfizer
  • Pieris Pharmaceuticals
  • Regeneron Pharmaceuticals
  • Roche
  • Servier
  • Wuhan YZY Biopharma
  • Xencor
  • Zymeworks
Back to Top